10-Q: Chemed Corporation Reports First Quarter 2024 Results, Driven by VITAS Growth

Chemed Corporation's first quarter 2024 results show a revenue increase driven by VITAS Healthcare, despite a decrease in Roto-Rooter revenue.

Summary

• Chemed Corporation reported a 5.2% increase in consolidated service revenues and sales for the first quarter of 2024, reaching $589.2 million.
• This growth was primarily driven by a 14.0% increase in VITAS Healthcare revenue, which was partially offset by a 5.8% decrease in Roto-Rooter revenue.
• VITAS experienced an 11.5% increase in days-of-care and a 2.6% increase in the geographically weighted average Medicare reimbursement rate.
• Roto-Rooter saw a decrease in all service lines, with a 4.6% decrease in short-term core services and an 8.0% decrease in water restoration services.
• Net income for the quarter was $65.0 million, or $4.24 per diluted share, compared to $54.1 million, or $3.58 per diluted share, in the same period last year.
• Adjusted EBITDA for the quarter was $114.6 million, representing 19.5% of revenue, compared to $100.1 million, or 17.9% of revenue, in the first quarter of 2023.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong growth in the VITAS segment and overall improvements in profitability. However, the decline in Roto-Rooter's revenue and the ongoing regulatory risks temper the overall positive outlook.

Positives

• VITAS Healthcare demonstrated strong revenue growth, driven by increased days-of-care and higher reimbursement rates.
• The expiration of the licensed healthcare worker retention bonus program positively impacted VITAS's gross margin.
• The company's net income and adjusted EBITDA showed significant year-over-year improvements.
• Chemed maintains a strong liquidity position with $404.8 million of unused lines of credit available.
• The company is in compliance with all debt covenants.
• The company completed two franchise acquisitions at Roto-Rooter.

Negatives

• Roto-Rooter experienced a decline in revenue across all service lines.
• Roto-Rooter's gross margin decreased due to declining revenue.
• The company's selling, general, and administrative expenses increased by 15.8% compared to the same period last year.
• There was a $38.6 million decline in accrued compensation due primarily to the payment of 2023 bonuses.

Risks

• VITAS is subject to ongoing audits and reviews by government agencies, which could result in penalties and repayment obligations.
• The company faces concentration risk with a significant portion of VITAS's accounts receivable from Medicare and Medicaid.
• A disruption from VITAS's main pharmaceutical and medical supply vendors could adversely impact operations.
• The company is subject to various lawsuits and claims in the normal course of business.
• The company's variable interest rate debt exposes it to interest rate risk.

Future Outlook

Management believes its liquidity and sources of capital are satisfactory for the company's needs in the foreseeable future and anticipates that operating income and cash flows will be sufficient to operate the business and meet commitments.

Management Comments

• Management believes its liquidity and sources of capital are satisfactory for the Company's needs in the foreseeable future.
• Management anticipates that operating income and cash flows will be sufficient to operate the business and meet any commitments for the foreseeable future.
• Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.

Industry Context

The report highlights the ongoing challenges in the healthcare industry, particularly the shortage of licensed healthcare workers, which impacted VITAS. The results also reflect the competitive nature of the plumbing and home services market, where Roto-Rooter experienced a decline in revenue. The company's performance is also influenced by regulatory changes and reimbursement policies in the hospice care sector.

Comparison to Industry Standards

• Chemed's VITAS segment's revenue growth of 14% is strong compared to the industry average for hospice care providers, which is typically in the single-digit range. For example, LHC Group, a major player in home health and hospice, reported a 10.5% increase in hospice revenue in their most recent quarter.
• The adjusted EBITDA margin of 19.5% is also competitive, with many healthcare service companies aiming for margins in the 15-20% range. Amedisys, another competitor in the home health and hospice space, reported an adjusted EBITDA margin of 17.5% in their most recent quarter.
• Roto-Rooter's revenue decline of 5.8% contrasts with some other home service companies that have seen growth, such as ServiceMaster, which reported a 3% increase in revenue in their most recent quarter. This suggests that Roto-Rooter may be facing specific challenges in its market.
• The company's share repurchase program is a common practice among public companies, but the scale of the repurchase, 50,000 shares, is relatively modest compared to some other companies in the sector. For example, some larger companies may repurchase millions of shares in a quarter.

Legal Proceedings

• VITAS is involved in an ongoing audit by the Office of the Inspector General (OIG) regarding the provision of elevated level-of-care hospice services.
• VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million related to the audit.
• VITAS has appealed the overpayment decision and deposited $50.3 million under the Immediate Recoupment process.
• The company is subject to various lawsuits and claims in the normal course of business.

Stakeholder Impact

• Shareholders will benefit from the increased net income and adjusted EBITDA.
• Employees at VITAS may see improved job security due to the segment's growth.
• Customers of VITAS will continue to receive hospice care services.
• Customers of Roto-Rooter may experience changes in service availability due to the revenue decline.
• Suppliers of VITAS may see increased demand due to the segment's growth.
• Creditors will be reassured by the company's compliance with debt covenants and strong liquidity position.

Next Steps

• The company will continue to monitor the performance of both VITAS and Roto-Rooter segments.
• Management will evaluate cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends.
• VITAS will continue to appeal the overpayment decision related to the OAS audit.
• The company will analyze the impact of new accounting standards on current footnote disclosures.

Key Dates

Keywords

Chemed, VITAS, Roto-Rooter, hospice care, plumbing, drain cleaning, revenue, EBITDA, net income, acquisitions, Medicare, Medicaid